Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Takeda to Invest ¥5 Bil. on Electric Power Facility
September 9, 2011
- Eisai to Accelerate Clinical Development with Milestone Payments, Signs Agreement on PIII Trials for Lenvatinib
September 8, 2011
- Eplerenone significantly Reduces Cardiovascular Death in High-Risk CHF Patients: Pfizer
September 7, 2011
- MTPC to Reorganize Its Subsidiary
September 7, 2011
- ASKA to Initiate Transparency GL Project on Full Scale in October
September 7, 2011
- Tarceva Approved for 1st-line in NSCLC: Roche
September 6, 2011
- Ogasawara to Become President, Ogawa to Step Down: RDKK
September 6, 2011
- Chugai Starts US-Japan PI Trials of Multiple In- Licenced Compounds from Roche
September 6, 2011
- Janssen Adds Precautions for CONCERTA for Administering to Patients Over 18
September 5, 2011
- Eisai Decides to Discontinue Development of Pariet Extended-Release Preparation
September 5, 2011
- Otsuka to Launch TS-1 in Europe in 2nd Quarter of 2012
September 5, 2011
- BMKK Encourages Its MRs to Use Hybrid Cars
September 5, 2011
- Otsuka to Create Special Subsidiary for Employees with Disabilities
September 5, 2011
- Astellas Files for Mirabegron in US and Europe
September 5, 2011
- NDA for Lurasidone Accepted in Canada: DSP
September 5, 2011
- Large-scale Users Should Accept “Unit Price-based, By-product Deals”: Mr Bessho of JPWA
September 5, 2011
- Over 10% of Pharmacists Switched to Generic Actos in Just 1 Week: Nextit
September 5, 2011
- CSD Report Highlights Growing Importance of Biopharmaceutical Market in 2010
September 5, 2011
- Sanwa Kagaku Licenses Anagliptin to Kowa in China, Taiwan
September 5, 2011
- MSD Launches Gardasil for Prevention of Cervical Cancer
September 5, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…